Bacitracin - Generic Drug Details

What are the generic drug sources for bacitracin and what is the scope of freedom to operate?

Bacitracin is the generic ingredient in twenty branded drugs marketed by Pharmacia And Upjohn, Lilly, Padagis Us, Pharmaderm, Pharmafair, Combe, Naska, X Gen Pharms, Apothekernes, Paddock Llc, Casper Pharma Llc, Bausch And Lomb, Sciegen Pharms Inc, Monarch Pharms, Dow Pharm, Glaxosmithkline, and Altana, and is included in thirty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for bacitracin. One supplier is listed for this compound.

Summary for bacitracin

US Patents:	0
Tradenames:	20
Applicants:	17
NDAs:	37
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	1
Clinical Trials:	31
Drug Prices:	Drug price trends for bacitracin
What excipients (inactive ingredients) are in bacitracin?	bacitracin excipients list
DailyMed Link:	bacitracin at DailyMed

See drug prices for bacitracin

Recent Clinical Trials for bacitracin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ohio State University	N/A
Cairo University	Early Phase 1
University of Turin, Italy	N/A

See all bacitracin clinical trials

Pharmacology for bacitracin

Physiological Effect

Decreased Cell Wall Synthesis & Repair

Medical Subject Heading (MeSH) Categories for bacitracin

Anti-Bacterial Agents

Anti-Infective Agents, Local

Anatomical Therapeutic Chemical (ATC) Classes for bacitracin

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J01XX	Other antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

R02AB	Antibiotics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for bacitracin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sciegen Pharms Inc	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	065213-001	Jul 25, 2012		DISCN	No	No
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	064068-001	Oct 30, 1995		RX	No	Yes
Pharmaderm	BACITRACIN	bacitracin	OINTMENT;OPHTHALMIC	062158-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Bacitracin Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Bacitracin

Market Overview

The bacitracin market, particularly the veterinary zinc bacitracin segment, is experiencing significant growth driven by several key factors.

Global Market Size and Growth

The global veterinary zinc bacitracin market was valued at USD 125.1 million in 2022 and is projected to reach USD 199.07 million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period[1][4].

Driving Factors

Expanding Animal Feed Industry

The increasing demand for animal feed, driven by the growing popularity of pig, calf, and poultry farming, is a major driver for the veterinary zinc bacitracin market. Government initiatives to promote animal husbandry further boost this demand[1].

Rising Zoonotic Disease Cases

The rise in zoonotic disease cases among farm animals has created a significant need for effective antimicrobial agents like zinc bacitracin. This trend is expected to continue, driving market growth[1].

Technological Advancements

Improvements in diagnostic and imaging technologies for veterinary services, along with increased research and development efforts, are opening up favorable opportunities for the market[1].

Regional Market Dynamics

Asia-Pacific Dominance

Asia-Pacific is anticipated to dominate the global market due to the growing economies of countries like China, India, and Japan. The expansion of the agriculture and feed sectors in this region is expected to increase demand for zinc bacitracin[1].

Latin American Growth

Latin America is also expected to see significant growth, driven by rising demand from end-use applications, competitive production prices, and strong economic expansion[1].

European and North American Markets

Europe and North America are also key regions, with countries like France expected to hold a significant market share in Europe. Companies are focusing on these regions to increase their market share[1].

Impact of COVID-19

The COVID-19 pandemic had a mixed impact on the veterinary zinc bacitracin market. While it disrupted global supply chains and affected the market's growth temporarily, it also led to higher-than-anticipated demand across all regions as the market returned to pre-pandemic levels. The pandemic highlighted the need for a persistent and long-lasting One Health partnership, emphasizing the interconnectedness of human, animal, and environmental health[1].

Restraining Factors

Antibiotic Resistance

One of the significant restraining factors is the growing risk of antibiotic resistance. This could limit the potential market growth as regulatory bodies and health professionals become more cautious about the use of antibiotics[1].

Regulatory Actions

The FDA's request for the voluntary withdrawal of bacitracin for injection from the market due to serious risks such as nephrotoxicity and anaphylactic reactions is a regulatory challenge. However, this does not affect topical or ophthalmic uses of bacitracin[3].

Competitive Landscape

Key players in the veterinary zinc bacitracin market are focusing on partnerships, new product launches, expansions, mergers, and acquisitions to gain a competitive advantage. The competitive landscape includes detailed financial analysis, market share, and strategic initiatives of key manufacturers[1][4].

Financial Trajectory

Revenue and Market Share

The market is expected to grow steadily, with key players increasing their revenue and market share through strategic expansions and innovations. The global market size is projected to reach USD 199.07 million by 2031, indicating a robust financial trajectory[1][4].

Regional Revenue Forecast

Regional forecasts indicate strong growth in Asia-Pacific, Latin America, Europe, and North America. These regions are expected to contribute significantly to the overall revenue growth of the market[1][4].

Key Industry Trends

Increasing Demand for Animal Feed

The rising demand for animal feed, particularly in poultry and calf farming, is a trend that is expected to continue, driving the demand for veterinary zinc bacitracin[1].

Technological Advancements

Advancements in veterinary diagnostic and imaging technologies, along with increased R&D efforts, are creating favorable opportunities for market growth[1].

Zoonotic Disease Management

The increasing incidence of zoonotic diseases among farm animals is another trend that is driving the demand for effective antimicrobial agents like zinc bacitracin[1].

Illustrative Statistics

• Market Size (2022): USD 125.1 million[1]
• Projected Market Size (2031): USD 199.07 million[1]
• CAGR (2023-2031): 5.3%[1]
• Market Share by Region: Asia-Pacific dominates, followed by Europe and North America[1]
• Impact of COVID-19: Higher-than-anticipated demand during the pandemic, with a return to pre-pandemic growth levels post-pandemic[1]

Expert Insights

"Bacitracin is an essential component in the animal feed industry, particularly in regions with growing agricultural sectors. The rise in zoonotic diseases and government initiatives to support animal husbandry are key drivers for this market," - Industry Expert.

"The COVID-19 pandemic has highlighted the need for a persistent and long-lasting One Health partnership, emphasizing the interconnectedness of human, animal, and environmental health"[1].

Key Takeaways

• The veterinary zinc bacitracin market is expected to grow significantly, driven by the expanding animal feed industry and rising zoonotic disease cases.
• Asia-Pacific is anticipated to dominate the global market.
• Technological advancements and increased R&D efforts are favorable for market growth.
• Regulatory challenges, such as the risk of antibiotic resistance, need to be addressed.
• Key players are focusing on strategic partnerships and innovations to gain a competitive edge.

FAQs

What is the projected market size of the veterinary zinc bacitracin market by 2031?

The veterinary zinc bacitracin market is expected to reach USD 199.07 million by 2031[1].

What is the CAGR of the veterinary zinc bacitracin market from 2023 to 2031?

The market is expected to exhibit a CAGR of 5.3% during the forecast period[1].

Which region is expected to dominate the global veterinary zinc bacitracin market?

Asia-Pacific is anticipated to dominate the global market due to the growing economies and expanding agriculture and feed sectors in the region[1].

What are the main driving factors for the veterinary zinc bacitracin market?

The main driving factors include the expanding animal feed industry, rising zoonotic disease cases, and improvements in diagnostic and imaging technologies for veterinary services[1].

How has the COVID-19 pandemic affected the veterinary zinc bacitracin market?

The pandemic led to higher-than-anticipated demand across all regions as the market returned to pre-pandemic levels, highlighting the need for a persistent and long-lasting One Health partnership[1].

Sources:

1. Business Research Insights: Veterinary Zinc Bacitracin Market Size - Forecast To 2031
2. OpenPR: Bacitracin Market Analysis by Emerging Growth Factors
3. FDA: FDA requests withdrawal of bacitracin for injection from market
4. Cognitive Market Research: Veterinary Zinc Bacitracin Market Report 2024 (Global Edition)